{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fontana RJ"],"funding":["Michigan Institute for Clinical and Health Research","NIDDK Training Grant","NIDDK NIH HHS","Tips Fund of Northwestern Medical Foundation","Jeanne Roberts and Rollin and Mary Ella King Funds of the Southwestern Medical Foundation","National Institute of Diabetes, Digestive and Kidney Diseases"],"pagination":["370-80"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4291312"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(2)"],"pubmed_abstract":["<h4>Background & aims</h4>The long-term clinical outcomes in initial survivors with acute liver failure (ALF) are not well known. The aim of this study was to provide an overview of the 2-year clinical outcomes among initial survivors and liver transplant (LT) recipients that were alive 3 weeks after enrolment in the Acute Liver Failure Study Group (ALFSG).<h4>Methods</h4>Outcomes in adult ALFSG patients that were enrolled between 1998 and 2010 were reviewed.<h4>Results</h4>Two-year patient survival was significantly higher in the 262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP) spontaneous survivors (SS) (89.5%) and 200 non-APAP SS (75.5%) (P < 0.0001). The causes of death were similar in the three groups but the time to death was significantly longer in the LT recipient"],"journal":["Liver international : official journal of the International Association for the Study of the Liver"],"pubmed_title":["Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study."],"pmcid":["PMC4291312"],"funding_grant_id":["T32 DK62708-01","DK U-01-58369","T32 DK062708","DK62708-01","U01 DK058369"],"pubmed_authors":["Reddy RK","Liou I","Lalani E","Larson AM","Goddard T","Ganger D","Han SH","Dillon C","McGuire B","Shaikh A","Reuben A","Pezzia C","Murray M","Murray N","Chung RT","McCashland T","Hassanein T","Fontana RJ","Durkalski V","Polson J","Munoz S","Rangnekar A","Hay JE","Zaman A","Reddy R","Satyanarayana R","Fontana R","Sanders C","Ostapowicz GA","Ellerbe C","Zhao W","US Acute Liver Failure Study Group","Han S","Schiodt FV","Ganger DR","Davern T","Harrison E","Schilsky M","Attar N","Reisch JS","Crippin J","Webster JW","Lee WM","Smith A","Rossaro L","Smith JP","Blei A","Fix O","Stravitz T","Stravitz R","Hynan LS","Samuel G","Durkalski VE","Brown R"],"additional_accession":[]},"is_claimable":false,"name":"Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study.","description":"<h4>Background & aims</h4>The long-term clinical outcomes in initial survivors with acute liver failure (ALF) are not well known. The aim of this study was to provide an overview of the 2-year clinical outcomes among initial survivors and liver transplant (LT) recipients that were alive 3 weeks after enrolment in the Acute Liver Failure Study Group (ALFSG).<h4>Methods</h4>Outcomes in adult ALFSG patients that were enrolled between 1998 and 2010 were reviewed.<h4>Results</h4>Two-year patient survival was significantly higher in the 262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP) spontaneous survivors (SS) (89.5%) and 200 non-APAP SS (75.5%) (P < 0.0001). The causes of death were similar in the three groups but the time to death was significantly longer in the LT recipient","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Feb","modification":"2025-04-27T19:36:22.518Z","creation":"2019-03-27T01:43:16Z"},"accession":"S-EPMC4291312","cross_references":{"pubmed":["25039930"],"doi":["10.1111/liv.12632"]}}